Understand the source comparison
Dosing Protocols: Subcutaneous vs Oral Administration
KPV for IBS is administered through two primary routes. Subcutaneous injection and oral capsules. And the choice between them depends on bioavailability requirements and patient tolerance. Subcutaneous KPV at 500–1000 mcg daily delivers systemic exposure with
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV for IBS is administered through two primary routes. Subcutaneous injection and oral capsules. And the choice between them depends on bioavailability requirements and patient tolerance. Subcutaneous KPV at 500–1000 mcg daily delivers systemic exposure with near-complete absorption, making it the preferred route for patients with severe mucosal inflammation or those who've failed oral therapies. Oral KPV requires higher doses (2000–4000 mcg daily) due to first-pass metabolism and enzymatic degradation in the stomach, but it offers convenience and localized gut exposure that may benefit patients with primarily intestinal symptoms.
- The subcutaneous protocol uses bacteriostatic water reconstitution at a concentration of 1 mg/mL, injected into abdominal subcutaneous tissue daily. The peptide's half-life is approximately 4–6 hours, meaning once-daily dosing maintains therapeutic plasma levels throughout the day. Oral KPV is typically formulated in enteric-coated capsules to protect the peptide from stomach acid degradation. Uncoated oral KPV loses 80–90% potency before reaching the small intestine.
- Patients report symptom improvement timelines of 10–14 days for subcutaneous administration and 3–4 weeks for oral protocols. The difference reflects absorption kinetics: subcutaneous delivery achieves steady-state plasma concentrations within 3–4 days, while oral delivery requires longer to accumulate sufficient peptide exposure at the gut lining. Neither route eliminates symptoms overnight. The peptide modulates inflammation, which takes time to translate into clinical improvement.